1
|
Buehne KL, Rosdahl JA, Hein AM, Woolson S, Olsen M, Kirshner M, Sexton M, Bosworth HB, Muir KW. How Medication Adherence Affects Disease Management in Veterans with Glaucoma: Lessons Learned from a Clinical Trial. Ophthalmic Res 2023; 66:489-495. [PMID: 36603568 DOI: 10.1159/000528857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 12/19/2022] [Indexed: 01/06/2023]
Abstract
INTRODUCTION We conducted a secondary, real-world clinical assessment of a randomized controlled trial to determine how a glaucoma medication adherence intervention impacted the clinical outcomes of participants at 12 months post-randomization. Participants included veterans at a VA eye clinic with medically treated glaucoma who reported poor adherence and their companions, if applicable. METHODS The treatment group received a glaucoma education session with drop administration instruction and virtual reminders from a "smart bottle" (AdhereTech) for their eye drops. The control group received a general eye health class and the smart bottle with the reminder function turned off. Medical chart extraction determined if participants in each group experienced visual field progression, additional glaucoma medications, or a recommendation for surgery or laser due to inadequate intraocular pressure control over the 12 months following randomization. The main outcome measure was disease progression, defined as visual field progression or escalation of glaucoma therapy, in the 12 months following randomization. RESULTS Thirty-six versus 32% of the intervention (n = 100) versus control (n = 100) groups, respectively, experienced disease intensification. There was no difference between the intervention and control groups in terms of intensification (intervention vs. control group odds ratio: 1.20; 95% confidence interval: [0.67, 2.15]), including when age, race, and disease severity were accounted for in the logistic regression model. Those whose study dates included time during the COVID-19 pandemic were evenly distributed between groups. CONCLUSIONS A multifaceted intervention that improved medication adherence for glaucoma for 6 months did not affect the clinical outcomes measured at 12 months post-randomization. Twelve months may not be long enough to see the clinical effect of this intervention or more than 6 months of intervention are needed.
Collapse
Affiliation(s)
- Kristen L Buehne
- Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, USA,
| | - Jullia A Rosdahl
- Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, USA
| | - Aaron M Hein
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
| | - Sandra Woolson
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA
| | - Maren Olsen
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA
| | - Miriam Kirshner
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA
| | - Malina Sexton
- Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, USA
| | - Hayden B Bosworth
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA
- Department of Population Health Sciences, Duke University, Durham, North Carolina, USA
| | - Kelly W Muir
- Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, USA
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA
| |
Collapse
|
2
|
Buehne KL, Rosdahl JA, Muir KW. Aiding Adherence to Glaucoma Medications: A Systematic Review. Semin Ophthalmol 2021; 37:313-323. [PMID: 34402384 DOI: 10.1080/08820538.2021.1963788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
PURPOSE To provide a comprehensive assessment of the strategies studied to date that focus on improving glaucoma medication adherence. METHODS A systematic review of the literature was conducted in MEDLINE (PubMed), Embase (Elsevier), and Scopus (Elsevier) from inception to March 1, 2021, of publications describing a device or strategy used to improve glaucoma medication adherence. RESULTS 42 studies described by 50 papers were included. Five categories were identified: reminder systems, medication simplifications, behavioral change programs, education, and alternative engagement strategies. CONCLUSION Most studies (40 of the 42) addressed the question of improved adherence directly, with 26 finding improved adherence. Notably, 14 examined the clinical effects of the intervention, either in terms of intraocular pressure (IOP) or visual fields. Only three found an improvement in IOP. None demonstrated a between group difference in visual field progression.
Collapse
Affiliation(s)
- Kristen L Buehne
- Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA
| | - Jullia A Rosdahl
- Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA
| | - Kelly W Muir
- Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.,Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA
| |
Collapse
|
3
|
Yang P, Shao Z, Besley NA, Neal SE, Buehne KL, Park J, Karageozian H, Karageozian V, Ryde IT, Meyer JN, Jaffe GJ. Risuteganib Protects against Hydroquinone-induced Injury in Human RPE Cells. Invest Ophthalmol Vis Sci 2021; 61:35. [PMID: 32818234 PMCID: PMC7443126 DOI: 10.1167/iovs.61.10.35] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Purpose Cigarette smoking has been implicated in the pathogenesis of AMD. Integrin dysfunctions have been associated with AMD. Herein, we investigate the effect of risuteganib (RSG), an integrin regulator, on RPE cell injury induced by hydroquinone (HQ), an important oxidant in cigarette smoke. Methods Cultured human RPE cells were treated with HQ in the presence or absence of RSG. Cell death, mitochondrial respiration, reactive oxygen species production, and mitochondrial membrane potential were measured by flow cytometry, XFe24 analyzer, and fluorescence plate reader, respectively. Whole transcriptome analysis and gene expression were analyzed by Illumina RNA sequencing and quantitative PCR, respectively. F-actin aggregation was visualized with phalloidin. Levels of heme oxygenase-1, P38, and heat shock protein 27 proteins were measured by Western blot. Results HQ induced necrosis and apoptosis, decreased mitochondrial bioenergetics, increased reactive oxygen species levels, decreased mitochondrial membrane potential, increased F-actin aggregates, and induced phosphorylation of P38 and heat shock protein 27. HQ, but not RSG alone, induced substantial transcriptome changes that were regulated by RSG cotreatment. RSG cotreatment significantly protected against HQ-induced necrosis and apoptosis, prevented HQ-reduced mitochondrial bioenergetics, decreased HQ-induced reactive oxygen species production, improved HQ-disrupted mitochondrial membrane potential, reduced F-actin aggregates, decreased phosphorylation of P38 and heat shock protein 27, and further upregulated HQ-induced heme oxygenase-1 protein levels. Conclusions RSG has no detectable adverse effects on healthy RPE cells, whereas RSG cotreatment protects against HQ-induced injury, mitochondrial dysfunction, and actin reorganization, suggesting a potential role for RSG therapy to treat retinal diseases such as AMD.
Collapse
Affiliation(s)
- Ping Yang
- Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
| | - Zixuan Shao
- Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
| | - Nicholas A Besley
- Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
| | - Samantha E Neal
- Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
| | - Kristen L Buehne
- Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
| | - John Park
- Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
| | - Hampar Karageozian
- Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
| | - Vicken Karageozian
- Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
| | - Ian T Ryde
- Nicholas School of the Environment, Duke University, Durham, North Carolina, United States
| | - Joel N Meyer
- Nicholas School of the Environment, Duke University, Durham, North Carolina, United States
| | - Glenn J Jaffe
- Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
| |
Collapse
|
4
|
Neal SE, Buehne KL, Besley NA, Yang P, Silinski P, Hong J, Ryde IT, Meyer JN, Jaffe GJ. Resveratrol Protects Against Hydroquinone-Induced Oxidative Threat in Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci 2020; 61:32. [PMID: 32334435 PMCID: PMC7401947 DOI: 10.1167/iovs.61.4.32] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Purpose Oxidative stress in retinal pigment epithelial (RPE) cells is associated with age-related macular degeneration (AMD). Resveratrol exerts a range of protective biologic effects, but its mechanism(s) are not well understood. The aim of this study was to investigate how resveratrol could affect biologic pathways in oxidatively stressed RPE cells. Methods Cultured human RPE cells were treated with hydroquinone (HQ) in the presence or absence of resveratrol. Cell viability was determined with WST-1 reagent and trypan blue exclusion. Mitochondrial function was measured with the XFe24 Extracellular Flux Analyzer. Expression of heme oxygenase-1 (HO-1) and glutamate cysteine ligase catalytic subunit was evaluated by qPCR. Endoplasmic reticulum stress protein expression was measured by Western blot. Potential reactions between HQ and resveratrol were investigated using high-performance liquid chromatography mass spectrometry with resveratrol and additional oxidants for comparison. Results RPE cells treated with the combination of resveratrol and HQ had significantly increased cell viability and improved mitochondrial function when compared with HQ-treated cells alone. Resveratrol in combination with HQ significantly upregulated HO-1 mRNA expression above that of HQ-treated cells alone. Resveratrol in combination with HQ upregulated C/EBP homologous protein and spliced X-box binding protein 1. Additionally, new compounds were formed from resveratrol and HQ coincubation. Conclusions Resveratrol can ameliorate HQ-induced toxicity in RPE cells through improved mitochondrial bioenergetics, upregulated antioxidant genes, stimulated unfolded protein response, and direct oxidant interaction. This study provides insight into pathways through which resveratrol can protect RPE cells from oxidative damage, a factor thought to contribute to AMD pathogenesis.
Collapse
|
5
|
Mozhdehi D, Luginbuhl KM, Simon JR, Dzuricky M, Berger R, Varol HS, Huang FC, Buehne KL, Mayne NR, Weitzhandler I, Bonn M, Parekh SH, Chilkoti A. Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature-triggered hierarchical self-assembly. Nat Chem 2018; 10:496-505. [PMID: 29556049 PMCID: PMC6676901 DOI: 10.1038/s41557-018-0005-z] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Accepted: 01/11/2018] [Indexed: 11/09/2022]
Abstract
Post-translational modification of proteins is a strategy widely used in biological systems. It expands the diversity of the proteome and allows for tailoring of both the function and localization of proteins within cells as well as the material properties of structural proteins and matrices. Despite their ubiquity in biology, with a few exceptions, the potential of post-translational modifications in biomaterials synthesis has remained largely untapped. As a proof of concept to demonstrate the feasibility of creating a genetically encoded biohybrid material through post-translational modification, we report here the generation of a family of three stimulus-responsive hybrid materials-fatty-acid-modified elastin-like polypeptides-using a one-pot recombinant expression and post-translational lipidation methodology. These hybrid biomaterials contain an amphiphilic domain, composed of a β-sheet-forming peptide that is post-translationally functionalized with a C14 alkyl chain, fused to a thermally responsive elastin-like polypeptide. They exhibit temperature-triggered hierarchical self-assembly across multiple length scales with varied structure and material properties that can be controlled at the sequence level.
Collapse
Affiliation(s)
- Davoud Mozhdehi
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, USA
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Kelli M Luginbuhl
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, USA
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Joseph R Simon
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, USA
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Michael Dzuricky
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, USA
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Rüdiger Berger
- Physics at Interfaces, Max Planck Institute for Polymer Research, Mainz, Germany
| | - H Samet Varol
- Department of Molecular Spectroscopy, Max Planck Institute for Polymer Research, Mainz, Germany
| | - Fred C Huang
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Kristen L Buehne
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Nicholas R Mayne
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Isaac Weitzhandler
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, USA
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
| | - Mischa Bonn
- Department of Molecular Spectroscopy, Max Planck Institute for Polymer Research, Mainz, Germany
| | - Sapun H Parekh
- Department of Molecular Spectroscopy, Max Planck Institute for Polymer Research, Mainz, Germany
| | - Ashutosh Chilkoti
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, USA.
- Department of Biomedical Engineering, Duke University, Durham, NC, USA.
| |
Collapse
|
6
|
Luginbuhl KM, Mozhdehi D, Dzuricky M, Yousefpour P, Huang FC, Mayne NR, Buehne KL, Chilkoti A. Recombinant Synthesis of Hybrid Lipid-Peptide Polymer Fusions that Self-Assemble and Encapsulate Hydrophobic Drugs. Angew Chem Int Ed Engl 2017; 56:13979-13984. [PMID: 28879687 PMCID: PMC5909378 DOI: 10.1002/anie.201704625] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 08/14/2017] [Indexed: 11/06/2022]
Abstract
Inspired by biohybrid molecules that are synthesized in Nature through post-translational modification (PTM), we have exploited a eukaryotic PTM to recombinantly synthesize lipid-polypeptide hybrid materials. By co-expressing yeast N-myristoyltransferase with an elastin-like polypeptide (ELP) fused to a short recognition sequence in E. coli, we show robust and high-yield modification of the ELP with myristic acid. The ELP's reversible phase behavior is retained upon myristoylation and can be tuned to span a 30-60 °C. Myristoylated ELPs provide a versatile platform for genetically pre-programming self-assembly into micelles of varied size and shape. Their lipid cores can be loaded with hydrophobic small molecules by passive diffusion. Encapsulated doxorubicin and paclitaxel exhibit cytotoxic effects on 4T1 and PC3-luc cells, respectively, with potencies similar to chemically conjugated counterparts, and longer plasma circulation than free drug upon intravenous injection in mice.
Collapse
Affiliation(s)
- Kelli M Luginbuhl
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Davoud Mozhdehi
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Michael Dzuricky
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| | - Parisa Yousefpour
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
| | - Fred C Huang
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
| | - Nicholas R Mayne
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
| | - Kristen L Buehne
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
| | - Ashutosh Chilkoti
- Department of Biomedical Engineering, Duke University, 1427 FCIEMAS, Box 90281, USA
- NSF Research Triangle Materials Research Science and Engineering Center, Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA
| |
Collapse
|
7
|
Luginbuhl KM, Mozhdehi D, Dzuricky M, Yousefpour P, Huang FC, Mayne NR, Buehne KL, Chilkoti A. Recombinant Synthesis of Hybrid Lipid–Peptide Polymer Fusions that Self‐Assemble and Encapsulate Hydrophobic Drugs. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201704625] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Kelli M. Luginbuhl
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
- NSF Research Triangle Materials Research Science and Engineering Center Department of Biomedical Engineering Duke University Durham NC 27708 USA
| | - Davoud Mozhdehi
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
- NSF Research Triangle Materials Research Science and Engineering Center Department of Biomedical Engineering Duke University Durham NC 27708 USA
| | - Michael Dzuricky
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
- NSF Research Triangle Materials Research Science and Engineering Center Department of Biomedical Engineering Duke University Durham NC 27708 USA
| | - Parisa Yousefpour
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
| | - Fred C. Huang
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
| | - Nicholas R. Mayne
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
| | - Kristen L. Buehne
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
| | - Ashutosh Chilkoti
- Department of Biomedical Engineering Duke University 1427 FCIEMAS, Box 90281 USA
- NSF Research Triangle Materials Research Science and Engineering Center Department of Biomedical Engineering Duke University Durham NC 27708 USA
| |
Collapse
|